Exploiting drug delivery systems for oral route in the peptic ulcer disease treatment

dc.contributor.authorSpósito, Larissa [UNESP]
dc.contributor.authorFortunato, Giovanna Capaldi [UNESP]
dc.contributor.authorde Camargo, Bruna Almeida Furquim [UNESP]
dc.contributor.authorRamos, Matheus Aparecido dos Santos [UNESP]
dc.contributor.authorSouza, Maurício Palmeira Chaves de [UNESP]
dc.contributor.authorMeneguin, Andréia Bagliotti [UNESP]
dc.contributor.authorBauab, Taís Maria [UNESP]
dc.contributor.authorChorilli, Marlus [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2021-06-25T10:57:36Z
dc.date.available2021-06-25T10:57:36Z
dc.date.issued2021-01-01
dc.description.abstractPeptic ulcer disease (PUD) is a common condition that is induced by acid and pepsin causing lesions in the mucosa of the duodenum and stomach. The pathogenesis of PUD is a many-sided scenario, which involves an imbalance between protective factors, such as prostaglandins, blood flow, and cell renewal, and aggressive ones, like alcohol abuse, smoking, Helicobacter pylori colonisation, and the use of non-steroidal anti-inflammatory drugs. The standard oral treatment is well established; however, several problems can decrease the success of this therapy, such as drug degradation in the gastric environment, low oral bioavailability, and lack of vectorisation to the target site. In this way, the use of strategies to improve the effectiveness of these conventional drugs becomes interesting. Currently, the use of drug delivery systems is being explored as an option to improve the drug therapy limitations, such as antimicrobial resistance, low bioavailability, molecule degradation in an acid environment, and low concentration of the drug at the site of action. This article provides a review of oral drug delivery systems looking for improving the treatment of PUD.en
dc.description.affiliationDepartment of Drugs and Medicines School of Pharmaceutical Sciences São Paulo State University (UNESP)
dc.description.affiliationDepartment of Biological Sciences School of Pharmaceutical Sciences São Paulo State University (UNESP)
dc.description.affiliationUnespDepartment of Drugs and Medicines School of Pharmaceutical Sciences São Paulo State University (UNESP)
dc.description.affiliationUnespDepartment of Biological Sciences School of Pharmaceutical Sciences São Paulo State University (UNESP)
dc.identifierhttp://dx.doi.org/10.1080/1061186X.2021.1904249
dc.identifier.citationJournal of Drug Targeting.
dc.identifier.doi10.1080/1061186X.2021.1904249
dc.identifier.issn1029-2330
dc.identifier.issn1061-186X
dc.identifier.scopus2-s2.0-85103881808
dc.identifier.urihttp://hdl.handle.net/11449/207581
dc.language.isoeng
dc.relation.ispartofJournal of Drug Targeting
dc.sourceScopus
dc.subjectdrug delivery system
dc.subjectHelicobacter pylori
dc.subjectmicroemulsion
dc.subjectmicroparticles
dc.subjectnanoparticles
dc.subjectnon-steroidal anti-inflammatory drugs
dc.subjectPeptic ulcer disease
dc.titleExploiting drug delivery systems for oral route in the peptic ulcer disease treatmenten
dc.typeResenha
unesp.author.orcid0000-0002-6118-9455[1]
unesp.author.orcid0000-0003-4279-6089[2]
unesp.author.orcid0000-0002-8442-0840[3]
unesp.author.orcid0000-0003-3359-3298[4]
unesp.author.orcid0000-0003-4983-3567[5]
unesp.author.orcid0000-0001-9284-2819[6]
unesp.author.orcid0000-0002-6698-0545[8]

Arquivos